(Finance) – Reduction for Illuminatewhich trades at a loss of 13.97% on previous values.
The biotechnology group has revised its estimates downwards for the current financial year: adjusted earnings per share are now expected between 0.60 and 0.70 dollars versus the 0.75-0.90 dollars of the previous guidance. Analysts’ expectations were 80 cents per share.
The weekly analysis of the stock compared to Nasdaq 100 shows a weakening compared to the index in terms of relative strength of thecompany specialized in the development of integrated systems dedicated to the analysis of genetic variationwhich performs worse than the reference market.
Analyzing the scenario of Illuminate there is a widening of the bearish phase at the test of the USD 89.05 support. First resistance at 94.99. Expectations are for an extension of the negative line towards new lows at 86.05.